Filing Flows › Iovance Biotherapeutics (IOVA) › Q1 2026
Iovance Biotherapeutics (IOVA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 7, 2026
Iovance Biotherapeutics (IOVA) reported revenue of $71.4M for the first quarter 2026 (Q1 2026), +45% from a year earlier and -18% from the quarter before. Operating margin was -113.5%, net loss $79.0M (110.7% of revenue).
Iovance Biotherapeutics, Q1 2026: revenue $71.4M (+45% year over year), operating margin -113.5%, net loss $79.0M, operating cash flow −$72.1M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $71.4M | -18% | +45% |
| Operating profit | −$81.0M | — | — |
| Net earnings | −$79.0M | — | — |
| Operating cash flow | −$72.1M | — | — |
What changed
Revenue was $71.4M in Q1 2026, up 45% year over year and down 18% from the previous quarter. Amtagvi was the largest line at 84% of revenue. Amtagvi added $16.7M year over year (up 38%), 75% of the total change.
Operating costs exceeded revenue by $81.0M, an operating margin of -113.5%. Total costs fell 11% while revenue rose 45%. The quarter ended with a net loss of $79.0M, wider than the previous quarter's $71.9M loss.
Operating cash flow was −$72.1M. Non-cash charges added back $2.8M of depreciation and amortization and $11.3M of share-based compensation. Working capital and other items used $7.1M. Capital expenditures of $6.6M exceeded it, leaving free cash flow of −$78.7M.
Questions
What was Iovance Biotherapeutics' revenue in the first quarter 2026?
Iovance Biotherapeutics (IOVA) reported revenue of $71.4M for the first quarter 2026 (Q1 2026), +45% from a year earlier and -18% from the quarter before.
Was Iovance Biotherapeutics profitable in the first quarter 2026?
Operating loss was $81.0M (-113.5% of revenue) and net loss $79.0M.